1 Comi G et al. (1995) Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Multiple Sclerosis1; (suppl 1): 24–27.
2.
2 Fernandez O et al. (1995) Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter randomized clinical trial. Multiple Sclerosis1; (suppl 1): 67–69.
3.
3 Fieschi C. (1995) Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis.Neuroimmunol (suppl 1): 14 (abstract).
4.
4 Filippi M et al. (1995a) Correlations between changes in disability and T2 — weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology45: 255–260.
5.
5 Filippi M et al. (1995b) Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain118: 1601–1612.
6.
6 Filippi M et al. (1995c) Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiat58: 31–37.
7.
7 Gass A et al. (1994) Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol36: 62–67.
8.
8 Jacobs L. (1995) New perspectives in treatment of MS: results with recombinant interferon beta-1a.J Neuroimmunol (suppl 1): 14 (abstract).
9.
9 Paty DW, Li DK, UBC MS/MRI study group and the IFNB multiple sclerosis study group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 662–667.
10.
10 Stone LA et al. (1995) The effects of interferon-β on blood-brain barrier disruption demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol37: 611–619.
11.
11 The IFNB Multiple Sclerosis study group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology43: 655–661.
12.
12 The IFNB Multiple sclerosis study group and the university of British Columbia MS/MRI analysis group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology45: 1277–1285.
13.
13 Van Walderveen MAA et al. (1995) Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/short TE (T1 — weighted) spin-echo images. Neurology45: 1684–1690.
14.
14 Weinshenker BG et al. (1991) The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain114: 1045–1050.
15.
15 Weinshenker BG et al. (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain112: 1419–1428.
